Target Product Profiles: Physician Insights on Key Attributes - Mild Cognitive Impairment, A therapy that improves ADAS-cog score from baseline at 12 months for the treatment of mild cognitive impairment.

Table of Contents

• Introduction
  • Using Target Product Profi les in Your Market Strategy
  • Report Contents
  • Target Product Profi le Methodology
• Etiology and Pathophysiology
  • Overview
  • Pathophysiology
    • MCI Progressing to Alzheimer' s Disease
    • MCI Progressing to Vascular Dementia
    • MCI Progressing to Fronto-Temporal Dementia
    • MCI Progressing to Dementia with Lewy Bodies
  • Etiology
    • Genetic Risk Factors in MCI Progressing to Alzheimer' s Disease and Vascular Dementia
    • Genetic Risk Factors in MCI Progressing to Fronto-Temporal Dementia
    • Genetic Risk Factors in MCI Progressing to Dementia with Lewy Bodies
• Target Product Profi le Discussion-Mild Cognitive Impairment
  • Target Product Profi le Summary for Mild Cognitive Impairment-2011
  • Assessing Drug Development Opportunities
  • Physician Survey Results
    • Effi cacy
    • Safety and Tolerability
    • Delivery
    • Estimated Patient Share
  • Pricing Potential
  • Forecasted 2016 Pricing Environment
  • Competitors to Watch
  • Emerging Product Profi les